Effect of ABCC2 (MRP2) transport function on erythromycin metabolism

Clinical Pharmacology and Therapeutics

Volumn 89, Issue 5, 2011, Pages 693-701

  Franke, R M ^a   Lancaster, C S ^a   Peer, C J ^b   Gibson, A A ^a   Kosloske, A M ^a   Orwick, S J ^a   Mathijssen, R H ^c   Figg, W D ^b   Baker, S D ^a   Sparreboom, A ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A; ERYTHROMYCIN; MIDAZOLAM; MULTIDRUG RESISTANCE PROTEIN 2;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BILIARY EXCRETION; CONTROLLED STUDY; DRUG EXCRETION; DRUG METABOLISM; DRUG TRANSPORT; ENZYME ACTIVITY; HOMOZYGOSITY; ISOTOPE LABELING; KNOCKOUT MOUSE; LIVER METABOLISM; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ADULT; AGED; ANIMALS; CELL LINE; COHORT STUDIES; CYTOCHROME P-450 CYP3A; DOGS; ERYTHROMYCIN; FEMALE; GENETIC VARIATION; HOMOZYGOTE; HUMANS; MALE; MICE; MICE, KNOCKOUT; MIDAZOLAM; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; PROTEIN TRANSPORT; YOUNG ADULT;

EID: 79955475552     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.25     Document Type: Article

References (44)

1. Brunton, L.L., Lazo, J. & Parker, K. Protein synthesis inhibitors and miscellaneous antibacterial agents. In Goodman & Gilman's The Pharmacological Basis of Therapeutics 11 edn. (ed. Brunton, L.L.) 1173-1202 (McGraw-Hill Professional, New york, 2006).
2. Watkins, P.B., Murray, S.A., Winkelman, L.G., Heuman, D.M., Wrighton, S.A. & Guzelian, P.S. Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients. J. Clin. Invest. 83, 688-697 (1989). (Pubitemid 19061193)
3. Watkins, P.B. Erythromycin breath test and clinical transplantation. Ther. Drug Monit. 18, 368-371 (1996). (Pubitemid 26264651)
4. Lan, L.B., Dalton, J.T. & Schuetz, E.G. Mdr1 limits CyP3a metabolism in vivo. Mol. Pharmacol. 58, 863-869 (2000).
5. Kim, R.B. et al. Interrelationship between substrates and inhibitors of human CyP3a and P-glycoprotein. Pharm. Res. 16, 408-414 (1999). (Pubitemid 29162099)
6. Schuetz, E.G., Yasuda, K., Arimori, K. & Schuetz, J.D. Human MDR1 and mouse mdr1a P-glycoprotein alter the cellular retention and disposition of erythromycin, But not of retinoic acid or benzo(a)pyrene. Arch. Biochem. Biophys. 350, 340-347 (1998). (Pubitemid 28368662)
7. Paine, M.F., Wagner, D.A., Hoffmaster, K.A. & Watkins, P.B. Cytochrome P450 3a4 and P-glycoprotein mediate the interaction between an oral erythromycin breath test and rifampin. Clin. Pharmacol. Ther. 72, 524-535 (2002). (Pubitemid 36237724)
8. Kurnik, D., Wood, A.J. & Wilkinson, G.R. The erythromycin breath test reflects P-glycoprotein function independently of cytochrome P450 3a activity. Clin. Pharmacol. Ther. 80, 228-234 (2006). (Pubitemid 44301092)
9. Frassetto, L.A., Poon, S., Tsourounis, C., Valera, C. & Benet, L.Z. Effects of uptake and efflux transporter inhibition on erythromycin breath test results. Clin. Pharmacol. Ther. 81, 828-832 (2007). (Pubitemid 46788293)
10. Hariharan, S., Gunda, S., Mishra, G.P., Pal, D. & Mitra, A.K. Enhanced corneal absorption of erythromycin by modulating P-glycoprotein and MRP mediated efflux with corticosteroids. Pharm. Res. 26, 1270-1282 (2009).
11. König, J., Nies, A.T., Cui, Y., Leier, I. & Keppler, D. Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, Substrate specificity, And MRP2-mediated drug resistance. Biochim. Biophys. Acta 1461, 377-394 (1999).
12. Keppler, D., Cui, Y., König, J., Leier, I. & Nies, A. Export pumps for anionic conjugates encoded by MRP genes. Adv. Enzyme Regul. 39, 237-246 (1999).
13. Zimmermann, C., Van de Wetering, K., Van de Steeg, E., Wagenaar, E., Vens, C. & Schinkel, A.H. Species-dependent transport and modulation properties of human and mouse multidrug resistance protein 2 (MRP2/Mrp2, ABCC2/ abcc2). Drug Metab. Dispos. 36, 631-640 (2008). (Pubitemid 351468367)
14. Lan, T. et al. Interaction of macrolide antibiotics with intestinally expressed human and rat organic anion-transporting polypeptides. Drug Metab. Dispos. 37, 2375-2382 (2009).
15. Kobayashi, Y. et al. Isolation, Characterization and differential gene expression of multispecific organic anion transporter 2 in mice. Mol. Pharmacol. 62, 7-14 (2002). (Pubitemid 34680510)
16. Franke, R.M., Carducci, M.A., Rudek, M.A., Baker, S.D. & Sparreboom, A. Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer. J. Clin. Oncol. 28, 4562-4567 (2010).
17. Kobayashi, Y., Sakai, R., Ohshiro, N., Ohbayashi, M., Kohyama, N. & Yamamoto, T. Possible involvement of organic anion transporter 2 on the interaction of theophylline with erythromycin in the human liver. Drug Metab. Dispos. 33, 619-622 (2005). (Pubitemid 40593874)
18. Van Waterschoot, R.A. et al. Midazolam metabolism in cytochrome P450 3a knockout mice can be attributed to up-regulated CyP2C enzymes. Mol. Pharmacol. 73, 1029-1036 (2008). (Pubitemid 351397908)
19. Charles, K.A., Rivory, L.P., Brown, S.L., Liddle, C., Clarke, S.J. & Robertson, G.R. Transcriptional repression of hepatic cytochrome P450 3a4 gene in the presence of cancer. Clin. Cancer Res. 12, 7492-7497 (2006). (Pubitemid 46095425)
20. Baker, S.D. et al. Factors affecting cytochrome P-450 3a activity in cancer patients. Clin. Cancer Res. 10, 8341-8350 (2004). (Pubitemid 40053395)
21. Lemahieu, W.P., Maes, B.D., Ghoos, Y., Rutgeerts, P., Verbeke, K. & Vanrenterghem, Y. Measurement of hepatic and intestinal CyP3a4 and PGP activity by combined po + iv [14C]erythromycin breath and urine test. Am. J. Physiol. Gastrointest. Liver Physiol. 285, G470-G482 (2003). (Pubitemid 37021807)
22. Turgeon, D.K. et al. P450 3a activity and cyclosporine dosing in kidney and heart transplant recipients. Clin. Pharmacol. Ther. 56, 253-260 (1994). (Pubitemid 24323916)
23. Wagner, D. CyP3a4 and the erythromycin breath test. Clin. Pharmacol. Ther. 64, 129-130 (1998).
24. Baker, S.D. et al. Pharmacogenetic pathway analysis of docetaxel elimination. Clin. Pharmacol. Ther. 85, 155-163 (2009).
25. De Jong, F.A. et al. Irinotecan-induced diarrhea: functional significance of the polymorphic aBCC2 transporter protein. Clin. Pharmacol. Ther. 81, 42-49 (2007). (Pubitemid 46050866)
26. Franke, R.M., Gardner, E.R. & Sparreboom, A. Pharmacogenetics of drug transporters. Curr. Pharm. Des. 16, 220-230 (2010).
27. Rivory, L.P. et al. Optimizing the erythromycin breath test for use in cancer patients. Clin. Cancer Res. 6, 3480-3485 (2000).
28. Franke, R.M., Baker, S.D., Mathijssen, R.H., Schuetz, E.G. & Sparreboom, A. Influence of solute carriers on the pharmacokinetics of CyP3a4 probes. Clin. Pharmacol. Ther. 84, 704-709 (2008).
29. Endres, C.J., Endres, M.G. & Unadkat, J.D. Interplay of drug metabolism and transport: a real phenomenon or an artifact of the site of measurement? Mol. Pharm. 6, 1756-1765 (2009).
30. Lam, J.L., Okochi, H., Huang, Y. & Benet, L.Z. In vitro and in vivo correlation of hepatic transporter effects on erythromycin metabolism: characterizing the importance of transporter-enzyme interplay. Drug Metab. Dispos. 34, 1336-1344 (2006). (Pubitemid 44079874)
31. Haenisch, S. et al. Influence of polymorphisms of aBCB1 and aBCC2 on mRNa and protein expression in normal and cancerous kidney cortex. Pharmacogenomics J. 7, 56-65 (2007). (Pubitemid 46322080)
32. Laechelt, S., Turrini, E., Ruehmkorf, A., Siegmund, W., Cascorbi, I. & Haenisch, S. Impact of aBCC2 haplotypes on transcriptional and posttranscriptional gene regulation and function. Pharmacogenomics J. 11, 25-34 (2011).
33. Rau, T., Erney, B., Göres, R., Eschenhagen, T., Beck, J. & Langer, T. High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of aBCC2 polymorphisms on plasma concentrations. Clin. Pharmacol. Ther. 80, 468-476 (2006). (Pubitemid 44737489)
34. Innocenti, F. et al. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J. Clin. Oncol. 27, 2604-2614 (2009).
35. Fujita, K. et al. association of aTP-binding cassette, Sub-family C, Number 2 (aBCC2) genotype with pharmacokinetics of irinotecan in Japanese patients with metastatic colorectal cancer treated with irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI). Biol. Pharm. Bull. 31, 2137-2142 (2008).
36. Han, J.Y. et al. associations of aBCB1, ABCC2, And aBCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer 110, 138-147 (2007).
37. Han, J.Y., Lim, H.S., Park, Y.H., Lee, S.Y. & Lee, J.S. Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer. Lung Cancer 63, 115-120 (2009).
38. Van Bambeke, F., Michot, J.M. & Tulkens, P.M. antibiotic efflux pumps in eukaryotic cells: occurrence and impact on antibiotic cellular pharmacokinetics, Pharmacodynamics and toxicodynamics. J. Antimicrob. Chemother. 51, 1067-1077 (2003). (Pubitemid 36622060)
39. Fernández, S.B. et al. Role of the N-terminal transmembrane region of the multidrug resistance protein MRP2 in routing to the apical membrane in MDCKII cells. J. Biol. Chem. 277, 31048-31055 (2002). (Pubitemid 34970809)
40. Relling, M.V., Nemec, J., Schuetz, E.G., Schuetz, J.D., Gonzalez, F.J. & Korzekwa, K.R. O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3a4. Mol. Pharmacol. 45, 352-358 (1994). (Pubitemid 24063092)
41. Mathijssen, R.H. et al. Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3a4 phenotyping probes. J. Natl. Cancer Inst. 96, 1585-1592 (2004).
42. Hooker, A.C. et al. Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function: incorporating cytochrome P4503a activity measurements. Clin. Pharmacol. Ther. 84, 111-118 (2008). (Pubitemid 351861492)
43. Lepper, E.R. et al. Effect of common CyP3a4 and CyP3a5 variants on the pharmacokinetics of the cytochrome P450 3a phenotyping probe midazolam in cancer patients. Clin. Cancer Res. 11, 7398-7404 (2005). (Pubitemid 41507700)
44. Rawden, H.C. et al. Microsomal prediction of in vivo clearance and associated interindividual variability of six benzodiazepines in humans. Xenobiotica. 35, 603-625 (2005). (Pubitemid 41242917)